AQST Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aquestive Therapeutics, Inc.

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding the approval status of its drug Anaphylm, leading to a significant drop in stock price [1][1]. Allegations - The lawsuit claims that during the class period from June 16, 2025, to January 8, 2026, Aquestive created a false impression that it was on track to receive FDA approval for Anaphylm by the January 31, 2026 PDUFA date [1][1]. - The FDA identified deficiencies in the NDA for Anaphylm, which precluded any discussions on labeling and post-marketing commitments, indicating that approval would be delayed [1][1]. - On January 9, 2026, Aquestive announced receipt of a letter from the FDA confirming ongoing review and deficiencies, which led to a stock price decline of over 37%, from $6.21 to $3.91 per share [1][1]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [1][1]. - Participation in the case is not required to be eligible for recovery, and all representation is on a contingency fee basis [1][1].